Indigenous people in the northern region of Alberta, Canada, face increased health risks from injection drug use, syphilis, and HIV.
"Generic treatments for HIV, viral hepatitis, and cancer can be affordably -- and profitably -- mass-produced for broad, unobstructed availability," writes Tracy Swan in this interview with Andrew Hill.
The high cost of hepatitis C treatment has inspired lawsuits and protests. Now, activist have targeted the hedge fund investors who they say are reaping profits from the pricey pills. Rod McCullom reports.
How does pharmaceutical company math work? One activist takes Gilead to task for the price of its next hepatitis C drug.
In just the past month, a pair of drugs were approved that may forever change (for the better!) the way hepatitis C is treated. But as treatment advocate George Carter laments, the revolution may come at too high a price.
The Fair Pricing Coalition (FPC) today condemned Gilead Sciences for the price set for its direct acting antiviral (DAA) Sovaldi™ (sofosbuvir), a once-daily, first-in-class nucleotide polymerase inhibitor approved by the U.S. Food and Drug Administra...